Equity Overview
Price & Market Data
Price: $0.0412
Daily Change: +$0.0₃2 / 0.49%
Daily Range: $0.041 - $0.045
Market Cap: $3,113,966
Daily Volume: 2,350
Performance Metrics
1 Week: -8.22%
1 Month: 3.00%
3 Months: 87.27%
6 Months: 116.8%
1 Year: 49.82%
YTD: 87.27%
Company Details
Employees: 3
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development of a portfolio of small molecule dismutase (SOD) mimetics to improve radiotherapy in cancer. The company's lead product is tilarginine that is in Phase 1/2 trial of a pan-inhibitor of nitric oxide synthase to treat patients with highly resistant forms of breast cancer, including metaplastic breast cancer (MpBC) and other refractory subsets of triple-negative breast cancer (TNBC). It develops avasopasem manganese, a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC). The company was incorporated in 2012 and is based in Malvern, Pennsylvania.